
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding is a strong investment opportunity due to its promising pipeline candidates and potential for approvals in both the US and EU markets for its lead candidate apitegromab. The recent resubmission of the BLA and positive regulatory interactions provide key de-risking events, while the company's early-stage programs and strategic positioning in the muscle-directed space offer long-term growth potential. KOL feedback and alignment with patient-experienced unmet needs support a strong launch and broad applicability of apitegromab in treating SMA. Risks to achieving our price target include clinical, regulatory, competitive, and financial risks, but the company's potential to become a multi-blockbuster therapy in SMA makes it worth considering for investment.
Bears say
Scholar Rock Holding is facing challenges in gaining market acceptance due to the crowded and competitive market for spinal muscular atrophy treatments. Furthermore, its limited product portfolio and lack of revenue could lead to financial strain, especially if its clinical trials for its pipeline candidates do not yield positive results. Additionally, the company may face regulatory challenges and delays in obtaining approval, further hampering its potential for growth and profitability.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares